Mazama Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mazama Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-101,207	Closed	-$10.6M	–	25
2015 Q4	$10.6M	Buy	101,207 +96,118	+1,889%	+$10M	1.95%	6
2015 Q3	$536K	Buy	5,089 +1,030	+25%	+$138K	0.11%	164
2015 Q2	$555K	Sell	4,059 -4,154	-51%	-$515K	0.11%	174
2015 Q1	$1.02M	Sell	8,213 -2,518	-23%	-$267K	0.21%	132
2014 Q4	$970K	Sell	10,731 -12,705	-54%	-$1.06M	0.22%	134
2014 Q3	$1.69M	Buy	23,436 +9,259	+65%	+$608K	0.43%	73
2014 Q2	$881K	Buy	14,177 +13,859	+4,358%	+$837K	0.24%	110
2014 Q1	$22K	Sell	318 -20,567	-98%	-$1.52M	0.02%	207
2013 Q4	$1.47M	Hold	20,885	–	–	0.73%	52
2013 Q3	$1.51M	Buy	20,885 +9,158	+78%	+$609K	0.82%	44
2013 Q2	$654K	Buy	+11,727	New	+$731K	0.41%	94

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Mazama Capital Management's BMRN Position: Q1 2016 in Review

Mazama Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 101,207 shares — an estimated $10.6M sold.

Mazama Capital Management first reported a position in BMRN in Q2 2013 and held it in 11 quarters. The position peaked at $10.6M in Q4 2015. 391 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Mazama Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Mazama Capital Management sold 101,207 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $10.6M.
Mazama Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Mazama Capital Management's BioMarin Pharmaceuticals position peaked at $10.6M in Q4 2015.
391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Mazama Capital Management's 13F filing for Q1 2016.